Enabling the Nervous System to Repair Itself

We create innovative treatments for nervous system damage due to injury or disease.

Number of people in the US living with SCI, MS and Alzheimer’s

NervGen’s Mission

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

NervGen Pharma

NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company creating innovative treatments that enable the nervous system to repair itself following damage. NervGen’s lead drug candidate, NVG-291 is currently in a Phase 1 clinical trial. The company’s initial target indications are spinal cord injury, Alzheimer’s disease and multiple sclerosis.

Our Technology

The nervous system is a complex network of nerves and cells that carries messages to and from the brain and spinal cord to various parts of the body to take in sensory information, process information and control movement. Damage to the nervous system can result in disruption to any, or all, of these functions. For a long time, everyone believed the nervous system could not repair itself, but that’s not the case. 

Our Team

Bill Radvak

Interim Chief Executive Officer

Adam Rogers

Interim President

Dan Mikol​

Dan Mikol

Chief Medical Officer

Bill Adams​

Bill Adams

Chief Financial Officer

Nana Collett​

Nana Collett

Vice President, Program Management

Matvey Lukashev

Vice President, Research and Preclinical Development

Stay Connected

Subscribe to our mailing list to stay up to date

The Latest

News Release

February 14, 2023

NervGen announced that all subjects (male, premenopausal and post-menopausal females) in the Phase 1 clinical trial of the Company’s proprietary lead compound, NVG-291, have completed dosing. 


July 28, 2022

Unlike existing treatments that focus on rehabilitation or reducing the risk of an additional stroke, the experimental drug targets the "stickiness" that can prevent injured brain tissue from functioning as it should


February 15, 2023

NervGen Pharma Corporate Update with Bill Radvak and Torrey Hills Capital. Click below to watch.